Prognostic impact of lymphocytes in soft tissue sarcomas - Wikidata - awgldk - TriplyDB

Prognostic impact of lymphocytes in soft tissue sarcomas

Prognostic impact of lymphocytes in soft tissue sarcomas

http://www.wikidata.org/entity/Q33813250

about

Adoptive cell therapy for sarcoma Microenvironmental Targets in Sarcoma Epithelial ovarian cancer - more data, more questions?The prognostic impact of TGF-β1, fascin, NF-κB and PKC-ζ expression in soft tissue sarcomas.Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis.Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas.Circulating and tumor-infiltrating Foxp3⁺ regulatory T cell subset in Chinese patients with extranodal NK/T cell lymphoma.Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance.Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival Clinical evaluation of systemic and local immune responses in cancer: time for integration.Sarcoma immunotherapy: past approaches and future directions.Adoptive immunotherapy against sarcomas.Bone morphogenetic protein 7 is associated with the nodal invasion of colon cancer.High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator.Clinical implication of pretreatment neutrophil to lymphocyte ratio in soft tissue sarcoma.Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma.Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy

P2860

Q27009541-2830D386-5F83-45B8-AFA8-86FA21B7115C Q28081400-1535EEC2-293C-4C4A-B4A2-362A2B3960E1 Q30869183-7161DF9C-B7CE-4B36-8F20-B50A03613E7A Q33842051-6E5CB699-390D-4993-B28C-6670C7271D5E Q33894390-7A6F9A5B-1E77-4115-A6AA-FACE25C6CF66 Q34178633-0229C4BB-F6B9-43B4-83F8-4E6E4D28AA62 Q34188723-4B4BDC80-2FFD-4D10-B016-9FEDFC21D6D9 Q34255022-AF9CBF0E-8967-4F9B-9327-E0ADDA8D0708 Q35187570-17EA4DFA-A0A6-442B-AD38-BA99633CE5DF Q37359509-41B2B198-E57D-4D6D-9E7E-D5A2B99C2A27 Q37665652-9EDBEDE5-9DD2-4575-9D11-6CF777CD4BD4 Q37945304-2CB14AA4-1C4D-492C-A8ED-D894D72D711E Q37989867-3BF35E9A-D78D-49A2-BCC8-B65C5BD32B02 Q38150174-278FC1A2-ECE4-4FA1-8CFD-713331B61201 Q38207986-AE6498D2-9FB0-4E15-B0D6-950EBAE63891 Q38291193-BA4A42AB-7D96-424D-BED6-225238A73050 Q38719348-EC886DA6-E14E-4007-9F0E-6ED44C6897C7 Q42204309-90C4DB2B-28F2-491F-A724-3AA1C7F32993 Q45226908-F3C16991-2342-4C2A-8F20-F4CC8157AB2D Q47096040-7E36401C-8E23-46AF-AC68-E6B7E680D051 Q47936113-49E941DD-F571-4457-A44E-DD49C44E79A5 Q52682430-D1FD9913-CB47-46A2-AA84-ACEEF7DD008C Q53162784-EF7A632E-0172-427C-839C-B5EDB53DCDF2 Q54977284-1D74C787-4508-48CC-8EC8-15D479BEC2A9 Q58787920-129BFCF8-E968-4E81-9048-734289E7DCD0

P2860

Prognostic impact of lymphocytes in soft tissue sarcomas

http://www.wikidata.org/entity/Q33813250

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Prognostic impact of lymphocytes in soft tissue sarcomas

@ast

Prognostic impact of lymphocytes in soft tissue sarcomas

@en

type

label

Prognostic impact of lymphocytes in soft tissue sarcomas

@ast

Prognostic impact of lymphocytes in soft tissue sarcomas

@en

prefLabel

Prognostic impact of lymphocytes in soft tissue sarcomas

@ast

Prognostic impact of lymphocytes in soft tissue sarcomas

@en

P1433

Q33813250-86C5A0A9-89A8-43A9-8FCD-1FD8D8CA9B08

P1476

Q33813250-FFFA8498-1089-427A-83F2-9DBFC710075B

P2093

Q33813250-1137C0DF-EC08-4196-86CD-9FC1FF7DB649

Q33813250-65A95F20-4423-41CB-93B8-A7986D7C99FE

Q33813250-6AFD2E79-D40E-46F0-9201-5FBF39BFA971

Q33813250-9240FE1E-6C23-4A1F-8976-F1345826DD48

Q33813250-B3940D43-1444-4654-AF9D-C7F4D5D6E792

Q33813250-D0298628-9FC6-41AA-B1F1-A6EC864F07FC

P2860

Q33813250-00316EA7-3D76-4016-BFD2-170D92845FFB

Q33813250-05199C2F-546D-4E75-9A93-D8C59584CDE3

Q33813250-14B5AA33-960C-41F8-B2FC-589024B597A8

Q33813250-21E74B5D-CDC9-4D72-9FD1-6B6877D1597A

Q33813250-3D30B352-E537-4E40-B3DF-528C03C881C4

Q33813250-454E055E-D14F-48CB-9705-176AC6CF984C

Q33813250-5517E5FC-A714-43CA-940A-C467600B303F

Q33813250-55EE57B0-D207-4062-B823-FFA0F20788B6

Q33813250-64CADFAF-E6AA-48BD-9637-EF16C2390B4A

Q33813250-66D390A8-D953-438A-B559-9E205581C56C

P304

Q33813250-D9C68B84-2F35-4E2E-ABEB-512142A34B34

P31

Q33813250-C5FB01CA-5408-4068-B1AF-BED36E2DC3EC

P356

Q33813250-C06F04B1-9F8D-4B0B-B475-58D835A4C3B6

P407

Q33813250-4EDB5B9A-EB24-4E14-86E7-BB673BFD5824

P433

Q33813250-B93A2A8A-4BCB-41DB-AB78-CABC974B84F6

P478

Q33813250-3303B791-C956-4CF4-BB78-398ED890FC8F

P50

Q33813250-1A9349F0-BC58-411B-BB4D-4F765A6BFEB0

Q33813250-D86C3887-56D8-4DD0-A86C-CB1FBBDF7FD8

P577

Q33813250-07584C4F-612B-486A-9192-9B77B0BD56D1

P5875

Q33813250-5D4D32BD-302B-4385-9C36-BA2827D8F166

P698

Q33813250-8099ADAA-067A-4F44-92EE-F1A46419BE8B

P932

Q33813250-E2913CB4-869A-4F71-A1FB-D60AA9E657FF

P356

JOURNAL.PONE.0014611

P1433

P1476

Prognostic impact of lymphocytes in soft tissue sarcomas

@en

P2093

Andrej Valkov

http://www.w3.org/2001/XMLSchema#string

Eivind Smeland

http://www.w3.org/2001/XMLSchema#string

Khalid Al-Shibli

http://www.w3.org/2001/XMLSchema#string

Lill-Tove Busund

http://www.w3.org/2001/XMLSchema#string

Roy M Bremnes

http://www.w3.org/2001/XMLSchema#string

Tom Donnem

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunoediting: from immunosurveillance to tumor escape

Paradoxical roles of the immune system during cancer development

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors

Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma

Tumor escape from immune surveillance.

Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma

Tissue microarray technology for high-throughput molecular profiling of cancer.

Time dependence of prognostic factors for patients with soft tissue sarcoma: a Scandinavian Sarcoma Group Study of 338 malignant fibrous histiocytomas.

CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.

P304

e14611

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0014611

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Sveinung Wergeland Sørbye

Thomas K Kilvaer

P577

2011-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49814311

http://www.w3.org/2001/XMLSchema#string

P698

21298041

http://www.w3.org/2001/XMLSchema#string

P932

3029277

http://www.w3.org/2001/XMLSchema#string